Tevogen CEO Updates Strategic Acquisition Plans, Annual Revenue Over $50 Million
Dr. Ryan Saadi, Founder & CEO Tevogen, sent the following letter to shareholders: "Dear Shareholders, As we continue executing on Tevogen's long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update regarding our ongoing strategic initiatives. Over the past several months, we have been actively evaluating potential acquisitions designed to complement our existing immunotherapy and artificial intelligence platforms. If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time. Based on preliminary evaluations, the combined entities under consideration may generate aggregate annual revenues in excess of $50 million. While these discussions remain subject to customary due diligence, negotiation, and definitive agreements, we believe the opportunity aligns with our disciplined growth strategy. Tevogen was built on the belief that innovation and affordability are not mutually exclusive. As we expand, we remain committed to disciplined capital allocation, operational efficiency, and long-term shareholder value creation. We appreciate your continued trust and support as we pursue strategic initiatives intended to strengthen Tevogen's financial foundation while advancing our mission of developing accessible immunotherapies."
